Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines (Q39398836)

11 September 2017

title

Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines (English)

1 reference

11 September 2017

0 references

1 reference

Nathalie Rioux-Leclercq

9

object named as

Nathalie Rioux-Leclercq

1 reference

11 September 2017

Julien Edeline

2

0 references

Jean-Jacques Patard

3

object named as

Jean-Jacques Patard

1 reference

11 September 2017

Bénédicte Martin

1

1 reference

11 September 2017

Emmanuel Oger

4

1 reference

11 September 2017

Florence Jouan

5

1 reference

11 September 2017

Gaëlla Boulanger

6

1 reference

11 September 2017

Sélim Zerrouki

7

1 reference

11 September 2017

Cécile Vigneau

8

1 reference

11 September 2017

language of work or name

1 reference

10 February 2012

1 reference

Journal of Cancer Research and Clinical Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

138

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

907-916

1 reference

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Alterations in VHL as potential biomarkers in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Tumour suppression by the human von Hippel-Lindau gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

From theoretical synergy to clinical supra-additive toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Combination targeted therapy in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1162-X

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

12 December 2020

Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells

1 reference

12 December 2020

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

1 reference

12 December 2020

10.1007/S00432-012-1162-X

Identifiers

DOI

1 reference

11 September 2017

1 reference